{"success":true,"data":{"pressRelease":{"id":"21670","rtpr_id":"nNFC8b1NdX","ticker":"RGC","exchange":"NASDAQ","all_tickers":["RGC"],"title":"RGC UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Deadline on June 23, 2026","author":"Newsfile Corp","published_at":"2026-05-05T17:22:05.815Z","article_body":"Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson\n(https://api.newsfilecorp.com/redirect/OAP7Wc2zGX) Encourages Investors Who\nSuffered Losses In Regencell To Contact Him Directly To Discuss Their Options\n\nIf you purchased or acquired securities in Regencell\n(https://api.newsfilecorp.com/redirect/PqNe3IgrQe) between October 28, 2024\nand October 31, 2025 and would like to discuss your legal rights, call Faruqi\n& Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.\n1310).\n\n[You may also click here for additional information]\n(https://api.newsfilecorp.com/redirect/wE07RcB4eg)\n\nNew York, New York--(Newsfile Corp. - May 5, 2026) - Faruqi & Faruqi, LLP\n(https://api.newsfilecorp.com/redirect/gJRLQi5n3Q), a leading national\nsecurities law firm, is investigating potential claims against Regencell\nBioscience Holdings Limited (\"Regencell\" or the \"Company\") (NASDAQ: RGC) and\nreminds investors of the June 23, 2026 deadline to seek the role of lead\nplaintiff in a federal securities class action that has been filed against the\nCompany.\n\n(https://images.newsfilecorp.com/files/6455/296039_496947e30439994d_001full.jpg)\n\nFaruqi & Faruqi is a leading national securities law firm with offices in New\nYork, Pennsylvania, California and Georgia. The firm has recovered hundreds of\nmillions of dollars for investors since its founding in 1995. See\nwww.faruqilaw.com.\n\nAs detailed below, the complaint alleges that the Company and its executives\nviolated federal securities laws by making false and/or misleading statements\nand/or failing to disclose that: (i) Regencell was vulnerable and/or subject\nto market manipulation; (ii) the resulting volatility in the market for the\nCompany's ordinary shares exposed Regencell's investors to significant\nfinancial risk; (iii) all the foregoing subjected Regencell to a heightened\nrisk of regulatory and/or governmental scrutiny and enforcement action, as\nwell as significant legal, monetary, and reputational harm; and (iv) as a\nresult, Defendants' public statements were materially false and misleading at\nall relevant times.\n\nThe truth began to emerge on October 31, 2025, when Regencell disclosed in an\nSEC filing that \"following recent volatility in the market for our Ordinary\nShares, the Company received correspondence and a subpoena from the U.S.\nDepartment of Justice ('DOJ'), indicating that the DOJ is conducting an\ninvestigation into the trading in our Ordinary Shares.\" Regencell said that\n\"[t]he DOJ has requested the production of documents and communications\nconcerning these and other corporate operational, financial and accounting\nmatters\" and that the Company \"expect[s] to continue to incur significant\nlegal costs and other expenses in connection with responding to the\ninvestigation\" and \"may be required to pay fines, penalties, damages or\nsettlement costs in excess of our insurance coverage, if any, related to the\ninvestigation.\"\n\nOn this news, Regencell's ordinary share price fell $3.09 per share, or\n18.56%, to close at $13.56 per share on November 3, 2025.\n\nThe court-appointed lead plaintiff is the investor with the largest financial\ninterest in the relief sought by the class who is adequate and typical of\nclass members who directs and oversees the litigation on behalf of the\nputative class. Any member of the putative class may move the Court to serve\nas lead plaintiff through counsel of their choice, or may choose to do nothing\nand remain an absent class member. Your ability to share in any recovery is\nnot affected by the decision to serve as a lead plaintiff or not.\n\nFaruqi & Faruqi, LLP also encourages anyone with information regarding\nRegencell's conduct to contact the firm, including whistleblowers, former\nemployees, shareholders and others.\n\nTo learn more about the Regencell Bioscience class action, go to\nwww.faruqilaw.com/RGC or call Faruqi & Faruqi partner Josh Wilson directly at\n877-247-4292 or 212-983-9330 (Ext. 1310).\n\nFollow us for updates on LinkedIn\n(https://api.newsfilecorp.com/redirect/0pvXoFkgbA), on X\n(https://api.newsfilecorp.com/redirect/RYD3MiOpqv), or on Facebook\n(https://api.newsfilecorp.com/redirect/WAjNOcMjQZ).\n\nAttorney Advertising. The law firm responsible for this advertisement is\nFaruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or\npredict a similar outcome with respect to any future matter. We welcome the\nopportunity to discuss your particular case. All communications will be\ntreated in a confidential manner.\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/296039","article_body_html":"","raw_payload":{"data":{"id":"nNFC8b1NdX","title":"RGC UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Deadline on June 23, 2026","author":"Newsfile Corp","ticker":"RGC","created":"2026-05-05T17:22:05.815Z","tickers":["RGC"],"exchange":"NASDAQ","article_body":"Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson\n(https://api.newsfilecorp.com/redirect/OAP7Wc2zGX) Encourages Investors Who\nSuffered Losses In Regencell To Contact Him Directly To Discuss Their Options\n\nIf you purchased or acquired securities in Regencell\n(https://api.newsfilecorp.com/redirect/PqNe3IgrQe) between October 28, 2024\nand October 31, 2025 and would like to discuss your legal rights, call Faruqi\n& Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.\n1310).\n\n[You may also click here for additional information]\n(https://api.newsfilecorp.com/redirect/wE07RcB4eg)\n\nNew York, New York--(Newsfile Corp. - May 5, 2026) - Faruqi & Faruqi, LLP\n(https://api.newsfilecorp.com/redirect/gJRLQi5n3Q), a leading national\nsecurities law firm, is investigating potential claims against Regencell\nBioscience Holdings Limited (\"Regencell\" or the \"Company\") (NASDAQ: RGC) and\nreminds investors of the June 23, 2026 deadline to seek the role of lead\nplaintiff in a federal securities class action that has been filed against the\nCompany.\n\n(https://images.newsfilecorp.com/files/6455/296039_496947e30439994d_001full.jpg)\n\nFaruqi & Faruqi is a leading national securities law firm with offices in New\nYork, Pennsylvania, California and Georgia. The firm has recovered hundreds of\nmillions of dollars for investors since its founding in 1995. See\nwww.faruqilaw.com.\n\nAs detailed below, the complaint alleges that the Company and its executives\nviolated federal securities laws by making false and/or misleading statements\nand/or failing to disclose that: (i) Regencell was vulnerable and/or subject\nto market manipulation; (ii) the resulting volatility in the market for the\nCompany's ordinary shares exposed Regencell's investors to significant\nfinancial risk; (iii) all the foregoing subjected Regencell to a heightened\nrisk of regulatory and/or governmental scrutiny and enforcement action, as\nwell as significant legal, monetary, and reputational harm; and (iv) as a\nresult, Defendants' public statements were materially false and misleading at\nall relevant times.\n\nThe truth began to emerge on October 31, 2025, when Regencell disclosed in an\nSEC filing that \"following recent volatility in the market for our Ordinary\nShares, the Company received correspondence and a subpoena from the U.S.\nDepartment of Justice ('DOJ'), indicating that the DOJ is conducting an\ninvestigation into the trading in our Ordinary Shares.\" Regencell said that\n\"[t]he DOJ has requested the production of documents and communications\nconcerning these and other corporate operational, financial and accounting\nmatters\" and that the Company \"expect[s] to continue to incur significant\nlegal costs and other expenses in connection with responding to the\ninvestigation\" and \"may be required to pay fines, penalties, damages or\nsettlement costs in excess of our insurance coverage, if any, related to the\ninvestigation.\"\n\nOn this news, Regencell's ordinary share price fell $3.09 per share, or\n18.56%, to close at $13.56 per share on November 3, 2025.\n\nThe court-appointed lead plaintiff is the investor with the largest financial\ninterest in the relief sought by the class who is adequate and typical of\nclass members who directs and oversees the litigation on behalf of the\nputative class. Any member of the putative class may move the Court to serve\nas lead plaintiff through counsel of their choice, or may choose to do nothing\nand remain an absent class member. Your ability to share in any recovery is\nnot affected by the decision to serve as a lead plaintiff or not.\n\nFaruqi & Faruqi, LLP also encourages anyone with information regarding\nRegencell's conduct to contact the firm, including whistleblowers, former\nemployees, shareholders and others.\n\nTo learn more about the Regencell Bioscience class action, go to\nwww.faruqilaw.com/RGC or call Faruqi & Faruqi partner Josh Wilson directly at\n877-247-4292 or 212-983-9330 (Ext. 1310).\n\nFollow us for updates on LinkedIn\n(https://api.newsfilecorp.com/redirect/0pvXoFkgbA), on X\n(https://api.newsfilecorp.com/redirect/RYD3MiOpqv), or on Facebook\n(https://api.newsfilecorp.com/redirect/WAjNOcMjQZ).\n\nAttorney Advertising. The law firm responsible for this advertisement is\nFaruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or\npredict a similar outcome with respect to any future matter. We welcome the\nopportunity to discuss your particular case. All communications will be\ntreated in a confidential manner.\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/296039"},"type":"article","timestamp":"2026-05-05T17:22:05.859045903Z","server_sent_at_ms":1778001725859},"received_at":"2026-05-05T17:22:05.912Z","source_url":"https://www.newsfilecorp.com/release/296039"},"analysis":{"id":"16120","press_release_id":"21670","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Faruqi & Faruqi, LLP issued a reminder to Regencell Bioscience investors regarding the June 23, 2026 lead plaintiff deadline in a federal securities class action.\n\nThe complaint alleges that Regencell failed to disclose vulnerabilities to market manipulation and a subsequent DOJ subpoena received in October 2025.\n\nThis release is a plaintiff-law-firm solicitation encouraging affected investors to contact the firm to discuss legal rights.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{},"quotedText":"Encourages Investors Who Suffered Losses In Regencell To Contact Him Directly To Discuss Their Options","namedEntities":{"people":[{"name":"James (Josh) Wilson","role":"Partner at Faruqi & Faruqi, LLP"}],"products":[],"companies":[{"name":"Faruqi & Faruqi, LLP","relationship":"plaintiff law firm"},{"name":"Regencell Bioscience Holdings Limited","ticker":"RGC"}],"dollarAmounts":[{"amount":"$3.09","context":"share price decline on November 3, 2025"},{"amount":"$13.56","context":"closing share price on November 3, 2025"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Faruqi & Faruqi. No new disclosure from the issuer; this is a routine lead-plaintiff-deadline reminder for an existing class action."},"tickerRelevance":{"others":[],"primary":"RGC"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Faruqi & Faruqi, LLP issued a reminder to Regencell Bioscience investors regarding the June 23, 2026 lead plaintiff deadline in a federal securities class action.\n\nThe complaint alleges that Regencell failed to disclose vulnerabilities to market manipulation and a subsequent DOJ subpoena received in October 2025.\n\nThis release is a plaintiff-law-firm solicitation encouraging affected investors to contact the firm to discuss legal rights.","key_figures":{},"named_entities":{"people":[{"name":"James (Josh) Wilson","role":"Partner at Faruqi & Faruqi, LLP"}],"products":[],"companies":[{"name":"Faruqi & Faruqi, LLP","relationship":"plaintiff law firm"},{"name":"Regencell Bioscience Holdings Limited","ticker":"RGC"}],"dollarAmounts":[{"amount":"$3.09","context":"share price decline on November 3, 2025"},{"amount":"$13.56","context":"closing share price on November 3, 2025"}]},"model_name":"glm-4.7","prompt_hash":"sha256:511026a279f8af46","schema_hash":"sha256:96555d0809de301c","created_at":"2026-05-05T19:40:24.939Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":52715,"modelName":"glm-4.7"}}